An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling.

Area of Science:

• Drug discovery and development
• Preclinical research
• Pharmaceutical sciences

Background:

• Vehicle selection is critical for preclinical compound profiling and candidate progression.
• Considerations include biopharmaceutical properties, compound availability, and animal model tolerability.
• Formulation must be adaptable for future clinical use.

Purpose of the Study:

• To outline a collaborative approach for selecting appropriate preclinical vehicles.
• To guide the development of formulations for early-stage drug candidates.
• To ensure the quality and speed of compound progression in preclinical studies.

Main Methods:

• Cross-functional team collaboration (Pharmacology, Pharmacokinetics, Toxicology, Pharmaceutical Sciences).
• Phased approach: dissolved API in early studies, developable formulations in later studies.
• Integration of pharmacological, toxicological, and pharmaceutical requirements.

Main Results:

• Early in vivo studies benefit from using dissolved active pharmaceutical ingredients (APIs).
• Later studies require developable formulations considering multiple scientific disciplines.
• Delivery strategies and analytical characterization are essential for interpreting results.

Conclusions:

• A multidisciplinary approach optimizes preclinical vehicle selection.
• Formulation development should align with clinical transformation goals.
• Robust analytical characterization supports the explanation of unexpected study outcomes.